Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone

Shinomiya, Hirotaka; Hasegawa, Shingo; Yamashita, Daisuke; Endo, Yasuo; Yoshida, Kenji; Otsuki, Naoki; Kiyota, Naomi; Sakakibara, Shunsuke; Nomura, Tadashi; Hashikawa, Kazunobu; Kohmura, Eiji; Sasaki, Ryohei; Nibu, Ken‐ichi

doi:10.1002/hed.24133

Cited by 45 publications

(54 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although certain study groups have reported the results of chemoradiotherapy as a non-surgical treatment, and Shinoyama et al [7] have reported a better prognosis with chemoradiotherapy than with other modalities, such as surgery with/without external-beam radiotherapy (EBRT), EBRT alone, or proton therapy, the number of studies are still limited.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of radiotherapy in advanced external auditory canal cancer

Nagano

Yoshimura

Kojima

et al. 2019

Journal of Radiation Research

View full text Add to dashboard Cite

External auditory canal cancer (EACC) is a rare malignant tumor. In the present study, we retrospectively evaluated the treatment results in patients with advanced EACC who were treated using external-beam radiotherapy (EBRT) combined with chemotherapy or radical surgery. Overall, 21 patients with Stage III ( n = 8) or Stage IV ( n = 13) EACC who underwent initial treatment at our hospital between 2003 and 2016 were enrolled in this study. The 2-year overall survival (OS) and locoregional control (LRC) rates of all patients were 62% and 71%, respectively. The 2-year OS and LRC rates in patients who had received EBRT and concurrent chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF, n = 6) were 100%. These results were higher than the 2-year OS and LRC rates of 62% and 69%, respectively, in patients who had received radical surgery and EBRT ( n = 13). The rates were 0% in those who had neither received TPF nor undergone surgery in addition to EBRT ( n = 2). Grade 3 bone or soft tissue necrosis was observed in 2 patients who had undergone surgery and postoperative EBRT. Our data suggest that the combination therapy of EBRT and surgery and/or chemotherapy may be the most effective treatment options for advanced EACC, and EBRT with concurrent chemotherapy with TPF is potentially the most acceptable.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcomes of radiotherapy in advanced external auditory canal cancer

Nagano

Yoshimura

Kojima

et al. 2019

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…Such findings raise the question of whether any surgery in the context of dural invasion is futile. Some argue that dural invasion is a contraindication to surgery …”

Section: Discussionmentioning

confidence: 99%

“…Whether aggressive surgery offers survival benefit in far‐advanced disease remains unknown and subject to ongoing debate, with some now suggesting definitive chemoradiation as first‐line therapy for advanced‐stage or unresectable disease . Morita et al found similar 5‐year overall survival rates for patients with T3–4 disease treated with definitive chemoradiation (52.1%) compared to those treated with surgical resection and adjuvant radiation with or without chemotherapy (55.6%).…”

Section: Introductionmentioning

confidence: 99%

“…Despite a slightly superior survival rate for surgically treated patients, they argued that chemoradiation may be preferred as a first‐line therapy due to significant morbidity and mortality of surgical resection of locally advanced disease, particularly in the case of unresectable tumors. The definition of unresectable disease varies by study, but is commonly defined as involvement of the petrous apex, carotid canal, dura, or brain parenchyma, with some also including the jugular canal and sigmoid sinus . Others challenge the definition of unresectability particularly in the case of skull base and dural involvement, and have demonstrated favorable survival outcomes for patients with intracranial extension treated with surgical resection .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Temporal bone carcinoma: Treatment patterns and survival

et al. 2019

View full text Add to dashboard Cite

Objectives/Hypothesis: Carcinomas of the temporal bone are rare, and appropriate treatment, staging, and survival data are limited. This study evaluates clinical characteristics and survival rates for patients with temporal bone carcinoma treated with resection at a single tertiary-care institution, with a focus on the outcomes of patients with locally advanced disease including skull base and/or dural invasion.Study Design: Retrospective chart review. Methods: Demographic, tumor-specific, and survival data were collected for patients with primary carcinomas of the external auditory canal with involvement of the temporal bone from 2003 to 2015. All patients were staged according to the modified Pittsburgh system. Kaplan-Meier and logistic regression analysis were used to calculate factor-specific survival outcomes.Results: Sixty-seven patients met inclusion criteria; 85% were male. There were 43 squamous cell carcinomas (64%) and 24 basal cell carcinomas (BCCs) (36%). Tumor stage was 24 (36%) T2, 12 (18%) T3, and 31 (46%) T4 tumors; 53% had recurrent disease. Surgical management included 49 lateral temporal bone resections and 18 subtotal temporal bone resections. Kaplan-Meier analyses revealed more favorable 5-year survival rates associated with BCC histology (P = .01), lateral temporal bone resection compared to subtotal temporal bone resection (P < .01), lack of immunocompromise (P = .04), and absence of perineural/lymphovascular invasion (P = .01). Multivariate regression analysis did not yield statistically significant results.Conclusions: Factors predictive of more favorable survival include lack of immunocompromise, BCC histology, absence of perineural/lymphovascular invasion, and disease extent amenable to lateral temporal bone resection. Dural invasion is not an absolute contraindication to surgery, with a subset of patients surviving >5 years.

show abstract

“…Morita et al 15 concluded that T1-2 tumors were well controlled by surgery, but recommended for T3-4 tumors to be treated by CRT. Shinomiya et al 16 reported the results of CCRT using the TPF regimen for advanced SCC of the temporal bone. Furthermore, Takenaka et al 17 performed a meta-analysis of CRT for SCC of the external auditory canal.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Patients with Squamous Cell Carcinoma of the Temporal Bone after Concomitant Chemoradiotherapy

et al. 2018

View full text Add to dashboard Cite

This article aims to clarify the long-term outcomes of patients with squamous cell carcinoma of the temporal bone who underwent concomitant chemoradiotherapy (CCRT). The study design was a retrospective chart review. From December 2001 to June 2014, 23 patients with cancer of the temporal bone who were treated by CCRT at the Tohoku University Hospital and the Iwate Medical University Hospital were enrolled in this study. For advanced cancer of the temporal bone, a modified docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen was used for CCRT. The long-term outcomes, including prognoses and late complications, were analyzed after CCRT of patients with cancers of the temporal bone. The main long-term complications were stenosis of the external auditory canal and conductive hearing loss. No harmful late complications were observed in these patients. Disease-specific survival rates were 84.9% for all patients, 100% for patients of stage I, II, and III ( = 10), and 75.5% for patients of stage IV ( = 13) at 5 years. Our study showed that CCRT is an effective treatment choice for squamous cell carcinoma of the temporal bone. Furthermore, CCRT using the TPF regimen is a safe and effective initial treatment for patients with advanced cancers of the temporal bone.

show abstract

Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone

Abstract: The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen. © 2015 Wiley Periodicals, Inc. Head Neck 38: E949-E953, 2016.

Cited by 45 publications

References 16 publications

Outcomes of radiotherapy in advanced external auditory canal cancer

Outcomes of radiotherapy in advanced external auditory canal cancer

Temporal bone carcinoma: Treatment patterns and survival

Long-Term Outcomes of Patients with Squamous Cell Carcinoma of the Temporal Bone after Concomitant Chemoradiotherapy

Contact Info

Product

Resources

About